Get the Stockscreener App
3.41
0.00%
0.00
After Hours:
3.41
Atea Pharmaceuticals Inc stock is traded at $3.41, with a volume of 457.89K.
It is up +0.00% in the last 24 hours and up +7.57% over the past month.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
See More
Previous Close:
$3.41
Open:
$3.39
24h Volume:
457.89K
Relative Volume:
1.07
Market Cap:
$266.41M
Revenue:
$351.37M
Net Income/Loss:
$-174.01M
P/E Ratio:
-1.6473
EPS:
-2.07
Net Cash Flow:
$-126.94M
1W Performance:
-3.94%
1M Performance:
+7.57%
6M Performance:
-8.82%
1Y Performance:
+0.29%
1-Day Range:
$3.35
$3.465
1-Week Range:
$3.285
$3.625
52-Week Range:
$2.455
$4.02
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Name
Atea Pharmaceuticals Inc
Sector
Industry
Phone
857-204-8109
Address
225 FRANKLIN STREET, BOSTON
Compare AVIR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
3.41 | 266.41M | 351.37M | -174.01M | -126.94M | -2.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-10-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-18-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-25-20 | Initiated | Evercore ISI | Outperform |
| Nov-24-20 | Initiated | JP Morgan | Overweight |
| Nov-24-20 | Initiated | Morgan Stanley | Overweight |
| Nov-24-20 | Initiated | William Blair | Outperform |
View All
Atea Pharmaceuticals Inc Stock (AVIR) Latest News
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Critical Survey: Atea Pharmaceuticals (NASDAQ:AVIR) vs. Regeneron Pharmaceuticals (NASDAQ:REGN) - Defense World
What analysts say about Atea Pharmaceuticals Inc stockTrading Volume Trends & Build a Smarter Portfolio Right Now - earlytimes.in
What drives Atea Pharmaceuticals Inc stock priceWeekly Market Snapshot & Access Free Risk Analysis Before You Invest - earlytimes.in
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Down 1.4%Here's What Happened - MarketBeat
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Down 1.4% – Here’s What Happened - Defense World
Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026 - Seeking Alpha
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus - Sahm
Is Atea Pharma Moving BEYOND The Virus And FORWARD To Breakthroughs? - RTTNews
Atea Pharmaceuticals Completes Enrollment in North American Phase 3 Trial of Hepatitis C Treatment - marketscreener.com
Atea Pharmaceuticals Completes Enrollment in C-BEYOND Phase 3 Trial for HCV Treatment, Anticipates Topline Results in Mid-2026 - Quiver Quantitative
Atea Pharmaceuticals Completes Patient Enrollment In North American Phase 3 Trial Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus - TradingView — Track All Markets
Atea Pharmaceuticals Completes Patient Enrollment in North - GlobeNewswire
Published on: 2025-12-21 17:47:39 - Улправда
Why analysts upgrade Atea Pharmaceuticals Inc. stockEarnings Overview Report & Stepwise Swing Trade Plans - Улправда
Is Atea Pharmaceuticals Inc. stock attractive for ETFsJuly 2025 Macro Moves & Safe Entry Trade Reports - Улправда
What is the fair value of Atea Pharmaceuticals Inc. stock nowTreasury Yields & Reliable Trade Execution Plans - Улправда
What technical charts say about Atea Pharmaceuticals Inc. stockJuly 2025 Breakouts & Safe Capital Growth Plans - Улправда
Aug Catalysts: What is the fair value of Atea Pharmaceuticals Inc. stock nowJuly 2025 Big Picture & Real-Time Stock Entry Alerts - Улправда
Is Atea Pharmaceuticals Inc. stock supported by strong cash flowsJuly 2025 Technicals & Reliable Entry Point Alerts - Улправда
How rising interest rates impact Atea Pharmaceuticals Inc. stockEntry Point & Long Hold Capital Preservation Plans - DonanımHaber
Will Atea Pharmaceuticals Inc. stock maintain growth storyTrade Performance Summary & Free Real-Time Volume Trigger Notifications - DonanımHaber
Will Atea Pharmaceuticals Inc. stock deliver strong dividend growthQuarterly Earnings Report & Safe Entry Point Identification - DonanımHaber
Chart Watch: Is Atea Pharmaceuticals Inc. stock supported by strong cash flowsJuly 2025 PreEarnings & Weekly Stock Breakout Alerts - Улправда
Nano Dimension And 2 Other Penny Stocks With Promising Potential - simplywall.st
Atea Pharmaceuticals Earnings Notes - Trefis
Atea Pharmaceuticals (AVIR) Stock Analysis Report | Financials & Insights - Benzinga
Atea Pharmaceuticals (NASDAQ:AVIR) Trading Down 1.9%Should You Sell? - MarketBeat
We're Keeping An Eye On Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Rate - Yahoo Finance
How Atea Pharmaceuticals Inc. stock trades during market volatilityTrade Risk Assessment & Community Verified Trade Signals - Newser
Is Atea Pharmaceuticals Inc. stock overvalued by current metricsJuly 2025 Macro Moves & Daily Growth Stock Tips - Newser
How Atea Pharmaceuticals Inc. stock valuations compare to rivalsTake Profit & Fast Entry High Yield Tips - Newser
How Atea Pharmaceuticals Inc. stock performs after earningsJuly 2025 Action & AI Enhanced Trading Signals - Newser
ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman - Stock Titan
Atea Pharmaceuticals director Franklin Berger acquires $81,498 in stock - MSN
Will Atea Pharmaceuticals Inc. stock beat EPS estimatesTrade Risk Report & Expert Approved Momentum Trade Ideas - newser.com
Is Atea Pharmaceuticals Inc. stock reversal real or fake2025 Winners & Losers & Technical Pattern Based Buy Signals - newser.com
Will Atea Pharmaceuticals Inc. stock outperform growth indexesJuly 2025 Action & Momentum Based Trading Ideas - newser.com
How strong is Atea Pharmaceuticals Inc. stock revenue growth2025 Historical Comparison & Growth Focused Investment Plans - newser.com
Atea Pharmaceuticals Inc (AVIR) Q3 2025 Earnings Call Highlights: Strategic Advances in HCV ... By GuruFocus - Investing.com Canada
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference - Yahoo Finance
Atea Pharma (NASDAQ: AVIR) hosts Evercore fireside chat Dec. 3 at 10:00 a.m. ET - Stock Titan
Is a relief rally coming for Atea Pharmaceuticals Inc. holdersProduct Launch & High Return Trade Opportunity Guides - newser.com
How Atea Pharmaceuticals Inc. stock performs in rate cut cyclesQuarterly Earnings Summary & Reliable Intraday Trade Alerts - newser.com
Atea Pharma (AVIR) Earnings Call Transcript - AOL.com
William Blair Has Negative Outlook of AVIR FY2025 Earnings - Defense World
Atea Pharmaceuticals Inc. stock trend outlook and recovery pathMarket Growth Report & Reliable Price Action Trade Plans - newser.com
Atea Pharmaceuticals Inc Stock (AVIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atea Pharmaceuticals Inc Stock (AVIR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BERGER FRANKLIN M | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
506,497 |
| Duncan Barbara Gayle | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Polsky Bruce | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
95,206 |
| Adams Jerome M. | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Lucidi Bruno | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
112,750 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):